Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Quality Control: SOP for Monitoring Container Closure System Integrity – V 2.0

Posted on By

Quality Control: SOP for Monitoring Container Closure System Integrity – V 2.0

Standard Operating Procedure for Monitoring Container Closure System Integrity in Sterile Injectables


Department Quality Control
SOP No. SOP/QC/168/2025
Supersedes SOP/QC/168/2022
Page No. Page 1 of 15
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

This SOP defines the process for monitoring container closure system (CCS) integrity for sterile injectable products to ensure they maintain sterility and prevent contamination. The procedure supports compliance with regulatory expectations, such as those from the FDA, USP <1207>,

and Annex 1 of EU GMP.

2. Scope

This SOP applies to all sterile injectable products manufactured at the facility, including vials, ampoules, and prefilled syringes, and covers container closure integrity testing (CCIT) at development, in-process, and finished product stages.

3. Responsibilities

  • QC Analyst: Executes container closure integrity tests as per approved protocols.
  • QC Supervisor: Reviews test data and ensures compliance with specifications.
  • QA Personnel: Verifies that results are recorded and investigated properly.
  • Engineering Team: Supports testing by maintaining test instruments.

4. Accountability

The Head of Quality Control is accountable for ensuring implementation of this SOP and compliance with regulatory standards regarding CCS integrity.

See also  Sterile Injectable Manufacturing: SOP for Online Inspection during Injectable Manufacturing - V 2.0

5. Procedure

5.1 Types of Container Closure Integrity Tests

  1. Deterministic Methods: These include vacuum decay, high-voltage leak detection (HVLD), laser-based headspace analysis, and pressure decay methods. Preferred due to accuracy and reproducibility.
  2. Probabilistic Methods: Includes dye ingress and microbial ingress methods. Used as supportive or investigational tools.

5.2 Selection of CCS Integrity Test

  1. Choose appropriate test method based on container type (vial, ampoule, syringe), product sensitivity, and critical quality attributes.
  2. Validate the method for specificity, sensitivity, repeatability, and detection limit.

5.3 Sample Preparation

  1. Collect representative samples from production batches, including edge vials and stress-tested containers.
  2. Ensure samples are labeled with batch number, container ID, and date of sampling.
  3. Inspect containers for pre-test visual integrity.

5.4 Deterministic Method Procedure – Vacuum Decay

  1. Place sealed containers in the vacuum chamber.
  2. Evacuate chamber to the validated vacuum level.
  3. Monitor pressure changes over time; a stable pressure indicates integrity.
  4. Compare results to control sample readings.

5.5 Dye Ingress Test Procedure (if required)

  1. Submerge containers in 0.1% methylene blue solution under vacuum conditions.
  2. Apply vacuum for 30 minutes followed by atmospheric pressure for another 30 minutes.
  3. Remove containers, rinse, and inspect for dye penetration visually and/or spectrophotometrically at 660 nm.
See also  Sterile Injectable Manufacturing: SOP for Operation of Vial Washing Machines in Sterile Production - V 2.0

5.6 Acceptance Criteria

  • No visible dye ingress or measurable pressure change in deterministic methods.
  • Acceptance criteria must align with validation protocol and regulatory guidance.

5.7 Handling of Failures

  1. Isolate failed samples and initiate an investigation using SOP/QC/051.
  2. Determine potential root causes: improper sealing, glass defects, crimping issues, etc.
  3. Document non-conformance and assess impact on batch disposition.

5.8 Documentation

  1. Record all observations, data, and instrument settings in Container Closure Integrity Test Log (Annexure-1).
  2. Attach instrument printouts and calibration status.
  3. Submit records to QA for review and archival.

5.9 Frequency of Testing

  • Performed as part of routine quality control of every production batch.
  • Stability samples to be tested at each scheduled interval.
  • Executed post-process change, machine maintenance, or sealing system validation.

5.10 Equipment Calibration and Maintenance

  • Maintain calibration schedule for CCIT equipment (Annexure-2).
  • Ensure daily performance checks and quarterly maintenance.

6. Abbreviations

  • CCIT: Container Closure Integrity Testing
  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • QC: Quality Control
  • HVLD: High Voltage Leak Detection
See also  Sterile Injectable Manufacturing: SOP for Stability Testing during Product Development - V 2.0

7. Documents

  1. Container Closure Integrity Test Log – Annexure-1
  2. Equipment Calibration Record – Annexure-2
  3. CCIT Failure Investigation Form – Annexure-3

8. References

  • USP <1207> – Container Closure Integrity Testing
  • FDA Guidance for Industry – Container Closure Systems for Packaging Human Drugs and Biologics
  • EU GMP Annex 1

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation QC Analyst QA Executive Head QA
Department Quality Control Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Container Closure Integrity Test Log

Date Batch No. Container Type Method Result Analyst
22/06/2025 INJ-845 Vial Vacuum Decay Pass Sunita Reddy

Annexure-2: Equipment Calibration Record

Instrument ID Model Last Calibration Next Due Calibrated By
CCIT-02 Micropress V900 15/04/2025 15/10/2025 Rajesh Kumar

Annexure-3: CCIT Failure Investigation Form

Date Batch Issue Observed Initial Assessment Corrective Action
20/06/2025 INJ-842 Leak Detected Improper Sealing Re-trained Operators

Revision History:

Revision Date Revision No. Details Reason Approved By
15/03/2022 1.0 Initial Release New Requirement Head QC
24/06/2025 2.0 Incorporated USP <1207> and Annex 1 references Annual Review Head QA
Injectables V 2.0 Tags:Aseptic processing SOP, Aseptic technique in sterile manufacturing, Cleanroom SOP for injectables, SOP for ampoule sealing, SOP for autoclave sterilization, SOP for container closure integrity testing, SOP for environmental monitoring in aseptic area, SOP for gowning in cleanroom, SOP for in-process checks in sterile manufacturing, SOP for injectable formulation, SOP for lyophilizer operation, SOP for sterile filtration, SOP for sterilization validation, SOP for vial filling, SOP for visual inspection of injectables, Sterile area cleaning SOP, Sterile filling line SOP, Sterile injectable quality control SOP, Sterile injection SOP, Sterile manufacturing procedure

Post navigation

Previous Post: Handling Training Gaps Detected in Internal or Regulatory Audits
Next Post: Gel Manufacturing: SOP for Weighing Micro Quantities of APIs for Gels – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version